JP2005341968A5 - - Google Patents

Download PDF

Info

Publication number
JP2005341968A5
JP2005341968A5 JP2005161155A JP2005161155A JP2005341968A5 JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5 JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005161155 A JP2005161155 A JP 2005161155A JP 2005341968 A5 JP2005341968 A5 JP 2005341968A5
Authority
JP
Japan
Prior art keywords
polypeptide
nucleic acid
seq
cell
neublastin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2005161155A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005341968A (ja
Filing date
Publication date
Priority claimed from US09/347,613 external-priority patent/US6593133B1/en
Application filed filed Critical
Publication of JP2005341968A publication Critical patent/JP2005341968A/ja
Publication of JP2005341968A5 publication Critical patent/JP2005341968A5/ja
Withdrawn legal-status Critical Current

Links

JP2005161155A 1998-07-06 2005-06-01 神経栄養因子 Withdrawn JP2005341968A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DKPA199800904 1998-07-06
US9222998P 1998-07-09 1998-07-09
DKPA199801048 1998-08-19
US9777498P 1998-08-25 1998-08-25
DKPA199801265 1998-10-06
US10390898P 1998-10-13 1998-10-13
US09/347,613 US6593133B1 (en) 1998-07-06 1999-07-02 Neurotrophic factors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000558205A Division JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005326745A Division JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子

Publications (2)

Publication Number Publication Date
JP2005341968A JP2005341968A (ja) 2005-12-15
JP2005341968A5 true JP2005341968A5 (enExample) 2006-02-02

Family

ID=27561795

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000558205A Pending JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子
JP2005161155A Withdrawn JP2005341968A (ja) 1998-07-06 2005-06-01 神経栄養因子
JP2005326745A Withdrawn JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子
JP2007120282A Withdrawn JP2007252381A (ja) 1998-07-06 2007-04-27 神経栄養因子
JP2007307603A Pending JP2008133282A (ja) 1998-07-06 2007-11-28 神経栄養因子

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000558205A Pending JP2002519061A (ja) 1998-07-06 1999-07-05 神経栄養因子

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2005326745A Withdrawn JP2006122053A (ja) 1998-07-06 2005-11-10 神経栄養因子
JP2007120282A Withdrawn JP2007252381A (ja) 1998-07-06 2007-04-27 神経栄養因子
JP2007307603A Pending JP2008133282A (ja) 1998-07-06 2007-11-28 神経栄養因子

Country Status (18)

Country Link
US (6) US6593133B1 (enExample)
EP (2) EP2290079A3 (enExample)
JP (5) JP2002519061A (enExample)
KR (1) KR100743376B1 (enExample)
AT (1) ATE522609T1 (enExample)
AU (1) AU755114B2 (enExample)
CA (1) CA2336218C (enExample)
CY (1) CY1112101T1 (enExample)
DK (1) DK1095140T3 (enExample)
EE (1) EE05590B1 (enExample)
ES (1) ES2373173T3 (enExample)
HU (1) HU227870B1 (enExample)
IS (1) IS2835B (enExample)
NZ (1) NZ508994A (enExample)
PT (1) PT1095140E (enExample)
SI (1) SI1095140T1 (enExample)
TR (1) TR200100056T2 (enExample)
WO (1) WO2000001815A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
US7067473B1 (en) * 1998-07-14 2006-06-27 Janssen Pharmaceutica N.V. Neurotrophic growth factor
PL209952B1 (pl) * 1998-07-14 2011-11-30 Janssen Pharmaceutica Nv Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
CA2367375A1 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
EP1820860A3 (en) * 1999-06-02 2008-03-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
AU2002232785B2 (en) * 2000-12-22 2006-05-18 Genentech, Inc. Use of artemin, a member of the GDNF ligand family for preparing a neuroprotective medicament
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
JP4259868B2 (ja) * 2001-02-01 2009-04-30 バイオジェン・アイデック・エムエイ・インコーポレイテッド ニューブラスチンのポリマー結合体および同様の使用方法。
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
ES2374971T3 (es) * 2001-03-28 2012-02-23 Biogen Idec Ma Inc. Uso de polipéptidos de neublastina para el tratamiento del dolor neuropático.
AU2003249013A1 (en) * 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Polynucleotides encoding a novel testis-specific tubulin tyrosine-ligase-like protein, bgs42
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
JP4742025B2 (ja) * 2003-01-31 2011-08-10 バイオジェン・アイデック・エムエイ・インコーポレイテッド 変異ニューブラスチンのポリマー結合体
EP1897552B1 (en) * 2003-04-18 2009-06-17 Biogen Idec MA Inc. Polymer-conjugated glycosylated neublastin
AU2004245175C1 (en) 2003-06-10 2010-03-18 Biogen Ma Inc. Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
CN101043899B (zh) 2004-08-19 2011-03-30 比奥根艾迪克Ma公司 重折叠转化型生长因子beta家族蛋白
DK1786454T3 (da) * 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
US8138148B2 (en) 2005-08-16 2012-03-20 Copenhagen University GDNF derived peptides
WO2007042040A2 (en) * 2005-10-11 2007-04-19 Ns Gene A/S TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
TWI445544B (zh) 2007-05-01 2014-07-21 Biogen Idec Inc 增進血管形成之組合物及方法
CA2691166A1 (en) * 2007-06-27 2008-12-31 Liu Dongxu Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
TWI698240B (zh) 2012-05-15 2020-07-11 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
PT3058371T (pt) 2013-10-14 2021-07-26 Univ Indiana Res & Tech Corp Uso de acamprosato para modular a ativação de erk 1-2 em modelos animais de sxf e tea e indivíduos diagnosticados com sxf e tea
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
EP3256147B8 (en) * 2015-01-18 2020-10-21 Gloriana Therapeutics, Inc. Therapeutic protein formulations
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352883A (en) 1979-03-28 1982-10-05 Damon Corporation Encapsulation of biological material
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4407957A (en) 1981-03-13 1983-10-04 Damon Corporation Reversible microencapsulation of a core material
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
DE3829766A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Verfahren zur herstellung von membranen
DE3829752A1 (de) 1988-09-01 1990-03-22 Akzo Gmbh Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5618531A (en) 1990-10-19 1997-04-08 New York University Method for increasing the viability of cells which are administered to the brain or spinal cord
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
WO1993006116A1 (en) 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
US5968502A (en) 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5284350A (en) * 1992-05-22 1994-02-08 Medical Composite Technology Foldable wheelchair and side frame assembly
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
CA2092271C (en) 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
DE4339605A1 (de) 1993-11-20 1995-05-24 Beiersdorf Ag Desodorierende Wirkstoffkombinationen auf der Basis von alpha, omega-Alkandicarbonsäuren und Fettsäurepartialglyceriden
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
US5780014A (en) 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5654007A (en) 1995-06-07 1997-08-05 Inhale Therapeutic Systems Methods and system for processing dispersible fine powders
US5739307A (en) 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US5733729A (en) 1995-09-14 1998-03-31 Affymetrix, Inc. Computer-aided probability base calling for arrays of nucleic acid probes on chips
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6878544B2 (en) * 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
IL126918A (en) 1996-05-08 2007-06-03 Biogen Idec Inc Ret ligand (retl) for stimulating neural and renal growth
US5754524A (en) 1996-08-30 1998-05-19 Wark; Barry J. Computerized method and system for analysis of an electrophoresis gel test
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US20020192209A1 (en) * 1997-09-17 2002-12-19 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020055467A1 (en) * 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
PL209952B1 (pl) 1998-07-14 2011-11-30 Janssen Pharmaceutica Nv Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu
JP2003524381A (ja) * 1998-09-22 2003-08-19 ユニヴァーシティ オブ メリーランド，ボルチモア システインノット成長因子ミュータント
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
PT1623990E (pt) * 1999-03-08 2008-03-18 Genentech Inc Composições e métodos para o tratamento de tumores
US6361771B1 (en) * 1999-04-06 2002-03-26 Neurotech S.A. ARPE-19 as a platform cell line for encapsulated cell-based delivery
DK1185648T3 (da) * 1999-06-02 2007-07-30 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst
JP2001329126A (ja) 2000-05-22 2001-11-27 Bridgestone Corp 硬化性組成物
EP1325966B1 (en) * 2000-09-12 2009-04-01 JFE Steel Corporation Super-high strength cold-rolled steel sheet and method for production thereof
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
US20040077543A1 (en) * 2001-03-28 2004-04-22 Sah Dinah W. Y. Treatment using neublastin polypeptides
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs

Similar Documents

Publication Publication Date Title
JP6946384B2 (ja) 脂質ナノ粒子を含む医薬組成物
CA2336218A1 (en) Neurotrophic factors
US11306296B2 (en) MG53 mutants, methods of making the same, and uses thereof
EP2910632B1 (en) Highly functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
JPH07502404A (ja) 幹細胞阻害タンパク質
WO2009100934A9 (en) Identification of a novel cysteine-rich cell penetrating peptide
CA2440767A1 (en) Novel neurotrophic factors
TW202222337A (zh) 一種提高bdnf水平的方法和藥物
EP4365190A1 (en) Recombinant botulinum toxin type a light chain, recombinant botulinum toxin, and composition, use, and method thereof
CN106574243A (zh) 表达腺病毒e4orf1的神经细胞及其制备方法和应用
TW202146648A (zh) 人類α-半乳糖苷酶變異體
EP2270141B1 (en) Partial peptide of lacritin
Luo et al. Identification of maze learning-associated genes in rat hippocampus by cDNA microarray
JP2003512841A5 (enExample)
JP2005511015A5 (enExample)
JP5678664B2 (ja) ヒトβ−ヘキソサミニダーゼＢの基質特異性を変換した新規高機能酵素
JP7847162B2 (ja) 組み換えボツリヌストキシンタイプａ軽鎖、組み換えボツリヌストキシン、並びにその組成物、その用途及びその方法
US20080102463A1 (en) Gene 4
JP2024516079A5 (enExample)
US20240132865A1 (en) Pharmaceutical composition for treating, preventing or ameliorating gm1 gangliosidosis or morquio syndrome b and administration method thereof
KR102728382B1 (ko) 보툴리눔 독소의 경쇄 변이체
JP2025533863A (ja) Ｇｍ１ガングリオシド症又はモルキオ症候群ｂ型の治療、予防又は改善用薬学的組成物及びその投与方法
JP2003164290A5 (enExample)
CA2332733A1 (en) Signal peptides, nucleic acid molecules and methods for treatment of caries
WO2024238698A2 (en) Transcription factor 4 gene editing system